Dizal Pharmaceutical Hits Day Low of CNY 53.23 Amid Price Pressure

Dizal (Jiangsu) Pharmaceutical Co., Ltd. experienced a significant decline today, with the stock dropping by 5.32% on July 28, 2026. The stock reached an intraday low of CNY 53.23, reflecting ongoing volatility in its performance. Over the past week, Dizal has seen a notable decrease of 13.24%, contrasting sharply with the China Shanghai Composite's decline of just 1.32%. In terms of longer-term performance, Dizal's one-year return stands at -29.24%, significantly underperforming the market, which has seen a positive return of 5.99%. The company's financial metrics indicate challenges, including a low Return on Capital Employed (ROCE) of 18.72% and a negative Return on Equity (ROE) of -56.70%. Additionally, the company has a high Debt to Equity ratio, which raises concerns about its financial stability. Despite a remarkable growth rate in net sales of 149.43% over the last five years, Dizal's operating profit has faced substantial challenges, reflecting a complex financial landscape. As a large-cap player in the miscellaneous industry, the company continues to navigate a difficult market environment.